Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel plus topotecan versus topotecan plus cisplatin for recurrent or persistent cervical cancer
ISRCTN77165120Phase 3Completed
- Sponsor
- Institute for Women's Health
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Cervical Cancer (CC) comparing Paclitaxel + topotecan with Topotecan + cisplatin (2 arms). Primary endpoint: Overall survival. Started Feb 2006; status: completed.
02
Drugs
paclitaxeltopotecancisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ISRCTN77165120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77165120.